Systemic chronic inflammation in end-stage renal disease patients and possible treatment approaches

I.  Dudar

doi:10.31450/ukrjnd.2(66).2020.08

I. Dudar SI «Institute of Nephrology NAMS of Ukraine» https://orcid.org/0000-0002-4372-8240

DOI: https://doi.org/10.31450/ukrjnd.2(66).2020.08

Keywords: systemic chronic inflammation, medium molecules, uremic toxins, hemodialysis, dialysis membranes, advanced hemodialysis.

Abstract

Systemic chronic inflammation (SCI) is a common feature of chronic kidney disease (CKD) which is most pronounced in dialysis patients. SCI is associated with cardiovascular pathology, various comorbid conditions and high mortality risk in dialysis patients.

The existing dialysis methods are ineffective for removing substances involved in SCI (medium molecular uremic toxins: cytokines, growth factors, adiponectin, hormones, and other substances).

The dialysis technology development has always aimed to create the membranes that will be as close as possible to the natural glomerular membrane.

Currently, Middle Cut-Off membranes have been created. The use of Middle Cut-Off membranes is implemented in a new method of dialysis therapy entitled expanded hemodialysis (HDx).

Further studies will determine the expected perspective of these membranes and HDx in the treatment of dialysis patients.

Downloads

Download data is not yet available.

References

Driianska VYe, Dudar IO, Shifris IM, Honchar YuI, Loboda OM, Haiseniuk FZ, Krot VF. Tsytokinova lanka imunitetu u khvorykh na KhKhN V st., yaki likuiutsia metodamy HD, HDF abo PD. Ukr. zhurn. nefrolohii ta dializu. 2016;4(52): 47-51. [In Ukrainian]. doi: 10.31450/ukrjnd.4(52).2016.03

Dudar I. Khronichne zapalennia pry khronichnii khvorobi nyrok. Hipotezy ta vidpovidi. Ukr. zhurn. nefrolohii ta dizu. 2007;1(13):33–42. [ In Ukrainian].

Dudar I, Shymova A, Krasiuk E. Porushennia nutrytsiinoho statusu u khvorykh, yaki likuiutsia perytonealnym dializam: rol khronichnoho zapalennia. Ukr. zhurn. nefrolohii ta dializu.2017;1(53):70-73. [ In Ukrainian]. doi: 10.31450/ukrjnd.1(53).2017.10

Korol L, Dudar I, Mihal L, Honchar Yu, Shifris I. Praktychna tsinnist vyznachennia oksydantno-antyoksydantnykh pokaznykiv krovi u khvorykh, yaki likuiutsia metodom hemodializu. Ukr. zhurn. nefrolohii ta dializu. 2018;1(57):48-56. [ In Ukrainian]. doi: 10.31450/ukrjnd.1(57).2018.05

Wolley MJ, Hutchison CA. Large uremic toxins: an unsolved problem in end-stage kidney disease. Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii6-iii11. doi: 10.1093/ndt/gfy179.

Driianska V, Korol L, Dudar I, Myhal L. ta in. Prozapalni tsytokiny (IL-1, FNP-alfa) ta oksydantno-antyoksydantnyi balans krovi khvorykh na khronichnu khvorobu nyrok V D stadii z riznym stanom komorbidnosti. Imunolohiia ta alerholohiia. Nauka i praktyka.2014;1:25-30. [In Ukrainian].

Malasaiev MO, Dudar IO, Shymova AYu. Perytonity, asotsiiovani z postiinym ambulatornym perytonealnym dializom. Ukr. zhurn. nefrolohii ta dializu.2019.3(63):47-52. [In Ukrainian]. doi: 10.31450/ukrjnd.3(63).2019.07

Suarez-Alvarez B, Liapis H, Anders H. Links between coagulation, inflammation, regeneration, and fibrosis in kidney pathology. Laboratory Investigation. 2016; 96:378–390. doi: 10.1038/labinvest.2015.164.

Gejyo F, Yamada T, Odani S. et al. A new form of amyloid protein associated with chronic hemodialysis was identifi ed as beta 2-microglobulin. Biochem Biophys Res Commun. 1985; 129(3): 701-706. doi: 10.1016/0006-291X(85)91948-5

Cheung AK, Rocco MV, Yan G. et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006;17(2): 546-555. doi: 10.1681/ASN.2005020132

Okuno S, Ishimura E, Kohno K. et al. Serum beta2-microglobulin level is a signifi cant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant. 2009;24(2):571-7. doi: 10.1093/ndt/gfn521.

Watanabe Y, Kawanishi H, Suzuki K. et al. Japanese Society for Dialysis Therapy Clinical Guideline for “Maintenance hemodialysis: hemodialysis prescriptions”. Ther Apher Dial. 2015; 19 (Suppl 1):67-92. doi: 10.1111/1744-9987.12294.

Masakane I, Sakurai K. Current approaches to middle molecule removal: room for innovation. Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii12-iii21. doi: 10.1093/ndt/gfy224.

Vanholder R, Schepers E, Pletinck A. et al. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014; 25:1897-1907. doi: 10.1681/ASN.2013101062

Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update. Toxins (Basel). 2018;10(1). pii: E33. doi: 10.3390/toxins10010033.

Vanholder RC, Eloot S, Glorieux GL. Future avenues to decrease uremic toxin concentration. Am J Kidney Disease. 2016; 67(4): 664-676. doi: 10.1053/j.ajkd.2015.08.029.

Kirsch AH, Lyko R, Nilsson LG. et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017; 32(1): 165-172. doi: 10.1093/ndt/gfw310

Mathur VS, Lindberg J, Germain M. et al. A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 1410–1419. doi: 10.2215/CJN.00100110